A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk

IF 0.8 Q4 GENETICS & HEREDITY

Meta Gene Pub Date : 2021-12-01 DOI:10.1016/j.mgene.2021.100962

Rabeya Akter , Md. Siddiqul Islam , Md. Safiqul Islam , Md. Abdul Aziz , Md. Saddam Hussain , Md. Shalahuddin Millat , Mohammad Sarowar Uddin , Mohammad Safiqul Islam

{"title":"A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk","authors":"Rabeya Akter , Md. Siddiqul Islam , Md. Safiqul Islam , Md. Abdul Aziz , Md. Saddam Hussain , Md. Shalahuddin Millat , Mohammad Sarowar Uddin , Mohammad Safiqul Islam","doi":"10.1016/j.mgene.2021.100962","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Prostate cancer is the most frequent non-cutaneous malignancy in men. Numerous genetic factors play a crucial role in the progression of prostate cancer. This study was undertaken to reveal the correlation of <em>TP53</em> rs1042522 and <em>CDH1</em> rs16260 polymorphisms with the risk of prostate cancer in the Bangladeshi population.</p></div><div><h3>Materials and methods</h3><p>We recruited 210 prostate cancer patients and 210 healthy controls for the investigation. Genotyping was conducted using the PCR-RFLP technique.</p></div><div><h3>Results</h3><p>In case of <em>TP53</em> gene rs1042522, the association analysis revealed that all genetic models were linked with significantly increased risk for prostate cancer development (CG vs. CC: OR = 1.99, <em>p</em> = 0.001; GG vs. CC: OR = 4.82, <em>p</em> < 0.00; CG vs. CC + GG: OR = 1.52, <em>p</em> = 0.041; CG + GG vs. CC: OR = 2.44, <em>p</em> < 0.00; GG vs. CC + CG: OR = 3.64, <em>p</em> = 0.00; G vs. C: OR = 2.32, <em>p</em> < 0.00). Again, the second variant rs16260 in <em>CDH1</em> gene also showed significantly enhanced association in all genetic models for the development of prostate cancer (CA vs. CC: OR = 2.20, <em>p</em> < 0.00; AA vs. CC: OR = 2.77, <em>p</em> = 0.012; CA vs. CC + AA: OR = 1.98, <em>p</em> = 0.001; CA + AA vs. CC: OR = 2.29, <em>p</em> = 0.00; A vs. C: OR = 1.99, <em>p</em> < 0.00) except the AA vs. CC + CA model.</p></div><div><h3>Conclusions</h3><p>Our study indicates a significant association of <em>TP53</em> rs1042522 and <em>CDH1</em> rs16260 polymorphisms with increased prostate cancer risk in the Bangladeshi population. However, replication studies are required in different populations to validate our findings.</p></div>","PeriodicalId":38190,"journal":{"name":"Meta Gene","volume":"30 ","pages":"Article 100962"},"PeriodicalIF":0.8000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.mgene.2021.100962","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Meta Gene","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214540021001134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 1

Abstract

Objectives

Prostate cancer is the most frequent non-cutaneous malignancy in men. Numerous genetic factors play a crucial role in the progression of prostate cancer. This study was undertaken to reveal the correlation of TP53 rs1042522 and CDH1 rs16260 polymorphisms with the risk of prostate cancer in the Bangladeshi population.

Materials and methods

We recruited 210 prostate cancer patients and 210 healthy controls for the investigation. Genotyping was conducted using the PCR-RFLP technique.

Results

In case of TP53 gene rs1042522, the association analysis revealed that all genetic models were linked with significantly increased risk for prostate cancer development (CG vs. CC: OR = 1.99, p = 0.001; GG vs. CC: OR = 4.82, p < 0.00; CG vs. CC + GG: OR = 1.52, p = 0.041; CG + GG vs. CC: OR = 2.44, p < 0.00; GG vs. CC + CG: OR = 3.64, p = 0.00; G vs. C: OR = 2.32, p < 0.00). Again, the second variant rs16260 in CDH1 gene also showed significantly enhanced association in all genetic models for the development of prostate cancer (CA vs. CC: OR = 2.20, p < 0.00; AA vs. CC: OR = 2.77, p = 0.012; CA vs. CC + AA: OR = 1.98, p = 0.001; CA + AA vs. CC: OR = 2.29, p = 0.00; A vs. C: OR = 1.99, p < 0.00) except the AA vs. CC + CA model.

Conclusions

Our study indicates a significant association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with increased prostate cancer risk in the Bangladeshi population. However, replication studies are required in different populations to validate our findings.

查看原文本刊更多论文

一项研究TP53 rs1042522和CDH1 rs16260多态性与前列腺癌风险相关性的病例对照研究

目的前列腺癌是男性最常见的非皮肤恶性肿瘤。许多遗传因素在前列腺癌的发展中起着至关重要的作用。本研究旨在揭示孟加拉国人群中TP53 rs1042522和CDH1 rs16260多态性与前列腺癌风险的相关性。材料与方法我们招募了210名前列腺癌患者和210名健康对照进行调查。采用PCR-RFLP技术进行基因分型。结果在TP53基因rs1042522的病例中，相关分析显示，所有遗传模型均与前列腺癌发展风险显著增加相关(CG vs. CC: OR = 1.99, p = 0.001;GG vs. CC: OR = 4.82, p <0.00;CG vs. CC + GG: OR = 1.52, p = 0.041;CG + GG vs. CC: OR = 2.44, p <0.00;GG vs. CC + CG: OR = 3.64, p = 0.00;G vs. C: OR = 2.32, p <0.00)。同样，CDH1基因的第二变体rs16260在所有遗传模型中也显示出与前列腺癌发展的显著增强关联(CA vs. CC: OR = 2.20, p <0.00;AA vs. CC: OR = 2.77, p = 0.012;CA vs. CC + AA: OR = 1.98, p = 0.001;CA + AA vs. CC: OR = 2.29, p = 0.00;A vs. C: OR = 1.99, p <0.00)， AA与CC + CA模型除外。结论在孟加拉国人群中，TP53 rs1042522和CDH1 rs16260多态性与前列腺癌风险增加存在显著相关性。然而，需要在不同人群中进行重复研究来验证我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Meta Gene Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Meta Gene publishes meta-analysis, polymorphism and population study papers that are relevant to both human and non-human species. Examples include but are not limited to: (Relevant to human specimens): 1Meta-Analysis Papers - statistical reviews of the published literature of human genetic variation (typically linked to medical conditionals and/or congenital diseases) 2Genome Wide Association Studies (GWAS) - examination of large patient cohorts to identify common genetic factors that influence health and disease 3Human Genetics Papers - original studies describing new data on genetic variation in smaller patient populations 4Genetic Case Reports - short communications describing novel and in formative genetic mutations or chromosomal aberrations (e.g., probands) in very small demographic groups (e.g., family or unique ethnic group). (Relevant to non-human specimens): 1Small Genome Papers - Analysis of genetic variation in organelle genomes (e.g., mitochondrial DNA) 2Microbiota Papers - Analysis of microbiological variation through analysis of DNA sequencing in different biological environments 3Ecological Diversity Papers - Geographical distribution of genetic diversity of zoological or botanical species.